Check out today’s featured companies who have recently completed an M&A deal, and be sure to check out the full list of past healthcare IT M&A.
Sectra Completes Oxipit Acquisition, Accelerating Autonomous AI in Radiology
International medical imaging IT and cybersecurity company Sectra has completed the acquisition of Oxipit, a pioneer in autonomous AI for radiology and the developer of the first solution with CE Class IIB certification for autonomous chest X-ray analysis. This milestone strengthens Sectra’s position as a provider of advanced, regulatory-approved AI solutions for diagnostic imaging.
“With the acquisition of Oxipit, we’re adding a new dimension to our AI offering: autonomous AI that can genuinely reduce radiologists’ workload in daily clinical practice. Equally important, we’re acquiring the clinical validation and regulatory expertise required to deploy this category of AI responsibly at scale. The acquisition complements our vendor-neutral AI marketplace, which remains a cornerstone of our strategy, and our own rapid innovation, such as MCP-powered system administration. Together, these moves demonstrate clear leadership in AI for diagnostic imaging and position us to help healthcare providers manage rising imaging volumes and address staff burnout,” says Torbjörn Kronander, President and CEO at Sectra.
With the acquisition complete, Sectra now owns and will further develop ChestLink, Oxipit’s flagship product and one of the most clinically validated examples of autonomous AI in radiology. Unlike conventional AI decision-support tools, which flag findings or assist prioritization but leave reporting to the radiologist, autonomous AI is developed and validated to independently complete a defined diagnostic task. ChestLink automatically identifies and clears high-confidence normal chest X-rays from the worklist, freeing radiologists to focus on cases with a higher probability of disease…
Full release here, originally announced April 15th, 2026.
ModMed Acquires Bonsai Health to Accelerate AI-Powered Patient Engagement
Addition of Agentic AI Platform Brings Automated Patient Reactivation and Self-Scheduling to the AI-Powered Practice
ModMed, a leading provider of software and services to specialty medical practices backed by Clearlake Capital Group, L.P., today announced the acquisition of Bonsai Health, a high-growth agentic AI patient engagement platform. This acquisition marks a major step forward in ModMed’s journey to create the AI-Powered Practice, integrating powerful new front-office automation capabilities such as automated patient reactivation and AI-driven self-scheduling.
“We are thrilled to welcome the incredible team at Bonsai Health into the ModMed family,” said Dan Cane, Co-Founder and Co-CEO at ModMed. “Bonsai was built on a simple but powerful mission: to ensure the right care happens at the right time. Their agentic AI platform and approach to patient reactivation are a perfect fit for our vision of the AI-Powered Practice. By bringing together the top-tier talent and solutions from both organizations, we’re creating an innovation powerhouse dedicated to delivering more value to the practices we serve.”
A Proactive Engine for Practice Growth
Bonsai Health acts as a proactive engine that works behind the scenes to automate front-office workflows. Utilizing an advanced agentic AI engine, the platform is designed to automatically identify care gaps in a patient’s history as well as openings in a provider’s schedule. It then leverages multi-channel SMS and email to seamlessly handle patient reactivation and self-scheduling without requiring manual staff intervention.
These capabilities complement ModMed’s existing patient engagement suite powered by Klara. While Klara serves as a centralized communication hub helping staff manage conversational workflows and patient outreach, Bonsai adds a specialized, proactive AI layer focused on improving patient outcomes, reducing staff workload, and filling gaps in the practice schedule—automatically…
Full release here, originally announced April 20th, 2026.
No comments:
Post a Comment